Email this article 
Hide
Show all
Case Report
A case report of untreatable HIV infection in Harare, Zimbabwe
Submitted: 16 July 2018 | Published: 27 June 2019
About the author(s)
Cleophas Chimbetete, Institute of Global Health, University of Geneva, Geneva, Switzerland; and, Newlands Clinic, Harare, ZimbabweLinda Chirimuta, Newlands Clinic, Harare, Zimbabwe
Margaret Pascoe, Newlands Clinic, Harare, Zimbabwe
Olivia Keiser, Institute of Global Health, University of Geneva, Geneva, Switzerland
Abstract
Introduction: Zimbabwe, like other resource limited countries, manages HIV infection using the public health approach with standard antiretroviral therapy (ART) regimens for first, second and third-line treatment. Third-line ART is the last available treatment option and is based on dolutegravir and darunavir use after HIV drug resistance testing.
Patient Presentation: We report here a 17-year-old patient on dolutegravir (DTG) and Darunavir based third-line antiretroviral therapy (ART) previously exposed to raltegravir who develops multidrug resistance HIV to the four ART classes available in Zimbabwe.
Management and Outcome: A trophism assay revealed that patient has CXCR4 trophic virus and hence will not benefit from Maraviroc. Patient is currently stable and receiving a holding regimen of abacavir, lamivudine and lamivudine.
Conclusion: This is the first documented case of multiclass resistance to the four available ART classes in Zimbabwe. The development and transmission of multiclass HIV drug resistance in resource limited settings has potential to undo the gains of national ART programs. There is need to ensure optimum adherence to ART even in the era of DTG.
Keywords
Metrics
Total abstract views: 5408Total article views: 5952
Crossref Citations
1. Pan-resistant HIV-1: what's next?
Raph L Hamers, Seth C Inzaule
The Lancet Microbe vol: 1 issue: 3 first page: e97 year: 2020
doi: 10.1016/S2666-5247(20)30058-6
2. Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort
Adam Abdullahi, Ibrahim Musa Kida, Umar Abdullahi Maina, Amina Husaini Ibrahim, James Mshelia, Haruna Wisso, Abdullahi Adamu, James Ezenwa Onyemata, Martin Edun, Haruna Yusuph, Sani H Aliyu, Man Charurat, Alash’le Abimiku, Lucie Abeler-Dorner, Christophe Fraser, David Bonsall, Lucie Abeler-Dörner, Helen Ayles, David Bonsall, Rory Bowden, Vincent Calvez, Max Essex, Sarah Fidler, Christophe Fraser, Kate Grabowski, Tanya Golubchik, Ravindra Gupta, Richard Hayes, Joshua Herbeck, Joseph Kagaayi, Pontiano Kaleebu, Jairam Lingappa, Sikhulile Moyo, Vladimir Novitsky, Thumbi Ndung'u, Deenan Pillay, Thomas Quinn, Andrew Rambaut, Oliver Ratmann, Janet Seeley, Deogratius Ssemwanga, Frank Tanser, Maria Wawer, Myron Cohen, Tulio D'Oliveira, Ann Dennis, Max Essex, Sarah Fidler, Dan Frampton, Christophe Fraser, Tanya Golubchik, Richard Hayes, Josh Herbeck, Anne Hoppe, Pontiano Kaleebu, Paul Kellam, Cissy Kityo, Andrew Leigh-Brown, Jairam Lingappa, Vladimir Novitsky, Nick Paton, Deenan Pillay, Tom Quinn, Oliver Ratmann, Deogratius Ssemwanga, Frank Tanser, Maria Wawer, Steven A Kemp, Ravindra K Gupta
Journal of Antimicrobial Chemotherapy vol: 78 issue: 8 first page: 2000 year: 2023
doi: 10.1093/jac/dkad195
3. Treatment of Advanced HIV in the Modern Era
Joseph M. Garland, Haim Mayan, Rami Kantor
Drugs vol: 85 issue: 7 first page: 883 year: 2025
doi: 10.1007/s40265-025-02181-1
4. Pan-Resistant HIV-1 Drug Resistance Among Highly Treated Patients with Virological Failure on Dolutegravir-Based Antiretroviral Therapy in Zimbabwe
Tendai Washaya, Benjamin Chimukangara, Justin Mayini, Sandra Bote, Nyasha Chin’ombe, Shungu Munyati, Justen Manasa
Viruses vol: 17 issue: 10 first page: 1348 year: 2025
doi: 10.3390/v17101348
5. Virologic outcomes on dolutegravir-, atazanavir-, or efavirenz-based ART in urban Zimbabwe: A longitudinal study
Tinei Shamu, Matthias Egger, Tinashe Mudzviti, Cleophas Chimbetete, Justen Manasa, Nanina Anderegg, Benjamin Chimukangara
PLOS ONE vol: 19 issue: 2 first page: e0293162 year: 2024
doi: 10.1371/journal.pone.0293162
6. Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings
Joseph Fokam, Ezechiel Ngoufack Jagni Semengue, Evariste Molimbou, Naomi-Karell Etame, Maria Mercedes Santoro, Désiré Takou, Leonella Mossiang, Alain Patrice Meledie, Collins Ambe Chenwi, Bouba Yagai, Alex Durand Nka, Beatrice Dambaya, Georges Teto, Aude Christelle Ka’e, Grâce Angong Beloumou, Sandrine Claire Djupsa Ndjeyep, Nadine Fainguem, Aissatou Abba, Aurelie Minelle Ngueko Kengni, Michel Carlos Tommo Tchouaket, Nounouce Pamen Bouba, Serge-Clotaire Billong, Rina Djubgang, Edith Temgoua Saounde, Samuel Martin Sosso, Charles Kouanfack, Anne-Cecile Zoung-Kanyi Bissek, Emmanuel Eben-Moussi, Vittorio Colizzi, Carlo-Federico Perno, Francesca Ceccherini-Silberstein, Alexis Ndjolo, Miguel Angel Martinez
Microbiology Spectrum vol: 10 issue: 6 year: 2022
doi: 10.1128/spectrum.03420-22